← Back to Clinical Trials
Recruiting NCT06486012

NCT06486012 Regular Use of aPDT in the Management and Prevention of Periodontitis Symptoms in Diabetic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06486012
Status Recruiting
Phase
Sponsor Wellbeing Services County of Pirkanmaa
Condition Diabetes Mellitus, Type 2
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-01-23
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Lumoral TreatmentStandard oral hygiene

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-01-23 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an investigator-initiated clinical study to establish easy referral and access for diabetic patients from primary health care to oral health care facilities for preventive oral care, periodontal assessment, and treatment, and to investigate the impact of regular home use of aPDT medical device on plaque control and gingival health, when used as an adjunct treatment to standard oral hygiene, and the effect on diabetes control in patients with the risk of periodontal disease, compared to a standard home care oral hygiene regimen.

Eligibility Criteria

Inclusion Criteria: * Diabetic patient treated at community health care; * At least 18 years old; * Presence of ≥20 teeth; * Agreement to participate in the study, and to sign a written consent form; * Ability to cooperate with the treatment protocol according to coordinator investigator's assessment. Exclusion Criteria: * Oral thrush; * Known sensitivity to near-infrared or antibacterial blue light.

Contact & Investigator

Central Contact

Miia Ehrnrooth

✉ miia.ehrnrooth@mehilainen.fi

📞 +358406615307

Principal Investigator

Anna Maria Heikkinen, Professor

PRINCIPAL INVESTIGATOR

Wellbeing Services of County Pirkanmaa

Frequently Asked Questions

Who can join the NCT06486012 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06486012 currently recruiting?

Yes, NCT06486012 is actively recruiting participants. Contact the research team at miia.ehrnrooth@mehilainen.fi for enrollment information.

Where is the NCT06486012 trial being conducted?

This trial is being conducted at Tampere, Finland.

Who is sponsoring the NCT06486012 clinical trial?

NCT06486012 is sponsored by Wellbeing Services County of Pirkanmaa. The principal investigator is Anna Maria Heikkinen, Professor at Wellbeing Services of County Pirkanmaa. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology